Molecules involved in the antigen receptor-dependent regulation of early T cell activation genes were investigated with the use of functional sequences of the T cell activation-specific enhancer of interleukin-2 (IL-2). One of these sequences forms a protein complex, NFAT-1, specifically with nuclear extracts of activated T cells. This complex appeared 10 to 25 minutes before the activation of the IL-2 gene. Studies with inhibitors ofprotein synthesis indicatedthat the time ofsynthesis ofthe activator of the IL-2 gene in Jurkat T cells corresponds to the time of appearance of NFAT-1. NFAT-1, or a very similar protein, bound functional sequences of the long terminal repeat (LTR) of the human immunodefidenc virus type 1; the LTR of this virus is known to be stimulated during early T The two ARREs within the IL-2 enhancer are approximately 200 bp apart and are the binding sites for different protein complexes, NFAT-1 and NF-IL2-A. Binding sites for other proteins lie between these two functional elements but are not discussed here. The sequences on the coding and noncoding strands of the NFAT-1 site (ARRE-2) that are protected from deoxyribonudease I (DNase I) digestion by nudear extracts of activated Jurkat cells extend from -288 to -267 and -263 to -290, respectively (Fig. 1, A and B) .
Molecules involved in the antigen receptor-dependent regulation of early T cell activation genes were investigated with the use of functional sequences of the T cell activation-specific enhancer of interleukin-2 (IL-2). One of these sequences forms a protein complex, NFAT-1, specifically with nuclear extracts of activated T cells. This complex appeared 10 to 25 minutes before the activation of the IL-2 gene. Studies with inhibitors ofprotein synthesis indicatedthat the time ofsynthesis ofthe activator of the IL-2 gene in Jurkat T cells corresponds to the time of appearance of NFAT-1. NFAT-1, or a very similar protein, bound functional sequences of the long terminal repeat (LTR) of the human immunodefidenc virus type 1; the LTR of this virus is known to be stimulated during early T cell activation. The binding site for this complex activated a linked promoter after transfection into antigen recptor-activated T cells but not other cell types. These characteristics suggest that NFAT-1 transmits signals initiated at the T ceRl antigen receptor.
I NTERACrION OF ANTIGEN WITH THE
antigen receptor of T lymphocytes initi- ates an ordered series of phenotypic changes resulting in cell division and immunologic function. The role of the antigen receptor in this process appears similar to that of many hormone receptors: antigen binding leads to hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) (1), generation of diacylglycerol and inositol 1,4,5-trisphosphate (I13) (2) , an increase in the concentration of intracellular calcium ion (3) , and phosphorylation of membrane and intracellular proteins (4) . These early events appear to be mediated through or at least require the T3 molecule, which is physically associated with the antigen receptor in the Ti-T3 complex (5) . A second signal is provided by macrophages that can, in part, be replaced by tumor promoters that activate protein kinase C (6 The two ARREs within the IL-2 enhancer are approximately 200 bp apart and are the binding sites for different protein complexes, NFAT-1 and NF-IL2-A. Binding sites for other proteins lie between these two functional elements but are not discussed here. The sequences on the coding and noncoding strands of the NFAT-1 site (ARRE-2) that are protected from deoxyribonudease I (DNase I) digestion by nudear extracts of activated Jurkat cells extend from -288 to -267 and -263 to -290, respectively (Fig. 1, A and B) .
To investigate the tissue distribution of NFAT-1 we used a double-stranded, bluntended oligonucleotide corresponding to the protected nucleotides (Fig. 1A) anid thec fr-action that contained theC nudear prottismwas precdpitatd with R442O (0.2 gtml) and dialyzed at 4PC for 4 -9 hours. For the DNase fbt ritn assay (23) we used pl(dI-dC) as a nonspecific competitor; BSA, bovine serum albumin alone, N, 20 1C). Neither the nuclear extracts of these stimulated cells or the extracts of rat brain, kidney, spleen, or liver formed a complex with ARRE-2, although the a-globin CAAT-binding protein and NF-IL2-A could be detected. The inability to detect NFAT-1 in rodent tissues is not related to an inability of the rodent factor to bind the human sequence since NFAT-1 could be readily detected in PMA-and ionomycinstimulated EL-4 and C6VL-B cells.
To examine the function of the binding site for NFAT-1 we prepared a plasmid in which three copies of ARRE-2 were placed upstream of a truncated y-fibrinogen promoter (12) . This promoter contains a TATA box and a functional Sp-l site and initiates ta rption correctly both in vivo and in vitro when truncated (13) . This construct was cotransfected into the cell lines shown in Table 1 using Rous sarcoma virus luciferase (14) to control for efficiency of transfection (15) . The ARRE-2 and the SV40 constructs function with similar efficiency in stimulated Jurkat cells (Table 1 ). In contrast, the pSV construct (15) functioned about 50-to 100-fold better than the ARRE-2 construct in PMA-and PHA (phytohemagglutinin)-stimulated KB cells, human Raji B cells, murine L cells, and Hep G2 cells (Table 1) . Thus three copies of the ARRE-2 sequence can confer T cell-specific function upon the normally uninduced fibrinogen promoter.
A role of NFAT-1 in the activation of the IL-2 gene is further suggested by a comparison of the kinetics of appearance of binding activity for the NFAT-1 protein and the activation ofthe IL-2 gene. Jurkat cells were stimulated with PHA and PMA at the times shown in Fig. 2 , and nuclear extracts as well as whole-cell RNA were prepared. The appearance of NFAT-1 was measured as the ability of the nudear extract to form a complex with the ARRE-2 region on low ionic strength gels (10) . By 20 min after stimulation, NFAT-1 was detectable and the amount produced steadily increased for 2 hours. The level of a CAAT-binding protein for the human a-globin promoter did not change during the time course shown in Fig.  2A ; therefore the changes in NFAT-1 binding were not due to degradation or a nonspecific PHA effect on nuclear DNA-binding proteins. In Jurkat cells, I:L-2 mRNA, measured by ribonuclease protection (16) , was first detectable between 30 and 45 min after exposure to PHA and PMA (Fig. 2, B) . The appearance of NFAT-1 10 to 25 min before IL-2 mRNA is consistent with a role of NFAT-1 in IL-2 gene activation. We investigated the requirements for NFAT-1 binding activity in Jurkat cells using anisomycin, which inhibits ribosomal subunit association and blocks 98% of protein synthesis of Jurkat cells at 100 ,M within 5 min (17) . When nuclear extracts from Jurkat cells were stimulated with PHA and PMA in the presence or absence of 100 ,uM anisomycin, we found that anisomycin inhibited the NFAT-1 binding activity by about 95% without affecting NF-IL2-A binding (Fig. 3A) . This small induction in the presence of anisomycin may represent leakage of protein synthesis or may be due to residual protein synthesis from a superinduced mRNA. When the same extracts were examined by DNase I protection, the sequences between -263 and -290 were not protected with the uninduced extracts or with extracts from Jurkat cells activated in the presence of 100 FM anisomycin. Using DRB (5,6-dichloro-1-D-ribofuranosylbenzimidaole), a rapidly acting inhibitor of RNA synthesis, we found that RNA synthesis was also essential for the appearance of NFAT-1 (18), indicating that a gene must be activated to obtain NFAT-1 binding activity. Although this gene is likely to be the one encoding NFAT-1, another possibility includes a gene required for synthesis of a protein necessary for the development of NFAT-1 binding activity.
Ifprotein synthesis is required for NFAT-1 binding activity and NFAT-1 is required for IL-2 gene activation, then protein synthesis should be required for IL-2 gene activation. We tested this prediction by exaiining the requirements for IL-2 gene activation using short periods ofexposure to anisomycin (less than 1 hour) to avoid many secondary effects commonly encountered when longer periods of exposure are used. As shown in Fig. 3B , anisomycin added as early as 20 min after stimulation inhibited the appearance of nearly all IL-2 mRNA (Fig. 3B ). In these same mRNA samples anisomycin did not inhibit c-fos gene activation or the constitutive expression of c-myc mRNA (19, 20) . These controls indicate that the failure to induce IL-2 mRNA in the anisomycin-treated samples was not du to a nonspecific effect on mRNA produ. ion. Since anisomycin at 100 ,uM takes only a few minutes to inhibit protein synthesis by 98% (17) , these results indicate that the protein required for IL-2 gene activation first appears at or before 20 min. This result is consistent with the first appearance of NFAT-1 at 20 min (Fig. 2) and strengthens the notion that NFAT-l is involved in IL-2 gene activation.
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We examined the regulatory sequences of the long terminal repeat (LTR) of the human immunodeficiency virus type 1 (HIV-1) for a binding site for NFAT-1, since previous workers had found that the lag time until appearance of the HIV-1 mRNA exceeds 30 min but is less than 2 hours (21, 22 ) after activation of HIV-1-infected T Fig. 3. (A Complexes were then separated on low ionic strength gels (10 (14) . To correct for differences in transfection efficiency we cotransfected a plasmid expressing 1-galactosidase (15) .
There was no detectable enhancer activity in pAlOCAT2 constructs in the region between Jpl and Cpl (Fig. lA) . Since a T cellspecific deoxyribonuclease (DNase) I hypersensitive site has been reported in the JP2 to Cp2 intron (16) 
